Exeliom Biosciences is a pioneering startup focused on developing innovative therapies that leverage the microbiome—the community of microorganisms living in our bodies—to treat diseases. The company primarily targets inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, which cause chronic inflammation of the digestive tract. Unlike traditional treatments that suppress the immune system, Exeliom's drug candidates aim to modulate, or adjust, the immune response without suppressing it. This makes their therapies more suitable for long-term use, especially for patients with mild to moderate symptoms.

Exeliom Biosciences operates in the biopharmaceutical market, a sector dedicated to developing drugs based on biological sources. Their clients include healthcare providers, hospitals, and patients suffering from chronic inflammatory conditions. The company collaborates with scientific experts, including Professor Harry Sokol from Saint Antoine Hospital in Paris, to ensure their therapies are grounded in cutting-edge research.

The business model of Exeliom Biosciences revolves around research and development (R&D) of new drug candidates. They invest heavily in scientific research to discover and develop these therapies. Once a drug candidate shows promise, it undergoes rigorous clinical trials to ensure its safety and efficacy. If successful, the company can then license the drug to pharmaceutical companies or sell it directly to healthcare providers. This is how Exeliom Biosciences generates revenue—through the commercialization of their innovative therapies.

In summary, Exeliom Biosciences is at the forefront of a new generation of medicine, focusing on the microbiome to create non-suppressive, immune-modulating therapies for chronic inflammatory diseases. Their patient-centric approach and commitment to scientific excellence position them as a promising player in the biopharmaceutical industry.

Keywords: microbiome, inflammatory bowel disease, immune modulation, chronic therapy, biopharmaceutical, innovative medicine, patient-centric, research and development, healthcare, non-suppressive.